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SummAry – The most common cause of rapidly progressive glomerulonephritis in elderly, anti-
neutrophil cytoplasmic antibody-associated glomerulonephritis (AnCA-gn), demands immuno-
suppressive therapy (iS) regimen in a multi-morbid disease burdened population. Our aim was to 
assess outcome differences in two age groups.
The study included a total of 38 AnCA-gn renal limited patients (18 men) treated from 1990 to 
2018, of which 11 were 65 years of age and older (median 70, min. - max. 66 - 79 years), and 27 
younger than 65 (median 55, min. - max. 23 - 64 years). All patients were treated with mono/combi-
nation of iS.
most commonly applied iS in elderly was combination of iv cyclophosphamide and corticoste-
roids (CS) (in 9 [81.8%]), while in younger it was a combination of CS and cyclophosphamide or 
rituximab (59.2%). Older patients had comparable mortality (3, [14.8%] vs. 4, [27.3%]; P = 0.369), 
malignancies (1, [3.7%] vs. 1, [9.1%]; P = 0.5) and infectious complications (10, [46.7%] vs. 7, [63.6%]; 
P = 0.388). ten patients at the end of the follow up were at renal replacement therapy (rrt), with no 
difference between age groups (6, [22.2%] vs. 4, [36.4%]; P = 0.369). interestingly, from initial need 
for rrt, half of the younger and older patients recovered with iS.
Our findings give more credit to the current paradigm to treat elderly AnCA-gn patients with 
iS therapy due to the similar outcome of elderly as younger ones.
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Introduction
Anti-neutrophil cytoplasmic antibody-associated 
glomerulonephritis (AnCA - gn) is a clinical entity 
in which AnCA-associated vasculitis (AAv) is limit-
ed to the kidneys, most commonly resulting in rapid 
progressive kidney failure1. due to the rapidly progres-
sive nature of the disease, fast diagnosis and treatment 
are crucial2. however, treatment with immunosup-
pressive agents also carries significant risks, especially 
in the elderly population of patients3. The incidence of 
AnCA-associated rapid progressive glomerulone-
phritis (rPgn) is known to increase with age, there-
fore being the most common cause of rPgn in the 
elderly4,5. Furthermore, current data suggest that 
younger patients frequently develop end-stage renal 
disease (eSrd) during follow-up4,6. On the other 
hand, older patients have increased mortality, possibly 
associated with the disease itself or possibly to the ad-
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ministered treatment4,6,7. The fact that morbidity and 
mortality were the highest in the first year after diag-
nosis in the majority of reported cases raises the ques-
tion of whether this was due to the disease process it-
self or it was a consequence of immunosuppressive 
treatment administration in a comorbid burdened co-
hort of patients4-6. 
As the world’s population is ageing, it would be 
helpful if recommendations regarding elderly and very 
elderly patients with AnCA-gn were addressed.
The aim of this study was to evaluate renal out-
comes in the elderly population with AnCA-gn 
treated with immunosuppressive therapy in compari-
son with a younger cohort.
Subjects and Methods
All adult patients (older than 18 years) diagnosed 
with limited renal AnCA-gn from 1990 to 2018 at 
the department of nephrology, Arterial hyperten-
sion, dialysis and transplantation of university hos-
pital Centre Zagreb were enrolled. retrospective data 
and follow-up were derived from medical records and 
the hospital information system. All patients were en-
rolled in our study if pathohistological analysis re-
vealed pauci-immune glomerulonephritis along with 
the exclusion of secondary causes and systemic in-
volvement. Patients were divided into two groups, 
younger than 65, and 65 or older, according to the 
world health Organisation definition of older pa-
tients.
The data were collected at presentation, during the 
first two years of diagnosis, and at the last control. Pa-
tients’ anthropometric measures, blood pressure, pre-
existing comorbid disease, signs of infection, and the 
applied therapy were derived from medical records. 
Furthermore, data regarding kidney function and dis-
ease activity were used, namely serum creatinine (SCr), 
proteinuria, red cells in urine sediment (rCu), and 
AnCA titre. renal function was assessed using 
CKd-ePi equation8 to estimate glomerular filtration 
(egFr), as well as staged according to KdigO stag-
ing9. Arterial hypertension was considered as blood 
pressure > 140/90 mmhg or using antihypertensive 
medication.
SCr was measured by the modified Jaffe assay and 
used to calculate egFr10. urinary protein concentra-
tions were determined using latex-enhanced immu-
nonephelometry on a Behring nephelometer ii (dade 
Behring, marburg, germany).
The pathohistological analysis of biopsy tissue was 
done by light microscopy using hematoxylin and eosin, 
methenamine silver, and periodic acid-Schiff stainings. 
Also, immunofluorescence with igg, igA, igm and 
complement staining, as well as electron microscopy 
was done.
Complete remission was defined as recovery of renal 
function, proteinuria < 0.25 g/du, and negative urine 
sediment. Partial remission was defined as proteinuria 
range 0.25 - 3.5 g/du, negative urine sediment, and 
50% reduction of the initial creatinine value11.
Therapy was defined as induction therapy, which 
was separated into intravenous (iv) forms of cortico-
steroids (CS) as monotherapy or in combination with 
either cyclophosphamide or rituximab. maintenance 
therapy was either monotherapy with azathioprine 
(AZA) or a combination of CS with AZA or myco-
phenolate mophetil (mmF).
each patient’s end-point was defined as death by 
any cause (split into malignancy, infection, cardiovas-
cular-related, or other), hemodialysis dependency or 
eSrd, or patient loss in follow-up.
data are expressed as median values with inter-
quartile range (iQr, 25 and 75 percentiles) for con-
tinuous variables and with numbers and percentages 
for categorical variables. Patients were divided into 
two groups according to age at the presentation 
(younger than 65 years, or 65 years and older). differ-
ences in medians between groups were assessed by the 
mann - whitney u test. A Fisher exact test was used 
for group comparisons regarding prevalence. Correla-
tions between parameters were examined using the 
Spearman’s rho test. The multivariate logistic regres-
sion analysis was performed to assess risk factors 
for eSrd in AnCA-gn for the whole group. The 
Kaplan - meier analysis was used to assess eSrd - 
free renal survival between older and younger cohort. 
All results were considered statistically significant if 
P < 0.05. Statistical analysis was performed using 
SPSS, vers.23 (SPSS. Chicago, inc).
Results
Patients were divided into two groups, those young-
er than 65 years (group 1) and 65 years and older (group 
2). elderly patients with AnCA-gn had higher sys-
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crescent lesions, without significant difference between 
groups (8, 72.8% vs. 13, 68.4%; P = 0.334).
we found that 74.3% of all patients had 1 or more 
comorbid diseases at the time of presentation, pre-
tolic BP and lower egFr than the younger cohort. 
Also, elderly patients had a higher body mass index 
(Bmi) than those younger than 65-year-old AnCA-
gn patients. There was no difference in renal function 
parameters such as sCr and proteinuria between groups 
at presentation (table 1). All patients had AnCA posi-
tive serology, almost all patients older than 65 years had 
pAnCA positive serology (10, 90.9%) without differ-
ence between the groups. nine patients (24.3%) pre-
sented with kidney failure requiring renal replacement 
therapy (rrt), with no difference between cohorts (3, 
27.3%, vs.6, 23.1%); P = 0.786).
no differences in percentage of crescentic forma-
tions were found between the groups (45%, 31.5 - 76, 
vs.48, 23 - 77.5; P = 0.734). when separating the 
forms of crescents, the majority of patients had active 
Table 3. Renal disease outcome at the end of the follow-up 
period
< 65 years 
old
≥ 65 years 
old total
n = 26 n = 11
total remission 6 (23.1%) 1 (9.1%) 7 (18.9%)
Partial remission 11 (42.3%) 6 (54.3%) 17 (45.9%)
no remission 
(active disease) 9 (34.6%) 4 (36.4%) 13 (35.1%)
of which eSrd 6 (23.1%) 4 (36.4%) 10 (27.0%)
Table 1: Significant clinical parameters at the time of presentation
< 65 years old ≥ 65 years old
P
n = 27 n = 11
Age, years 55 (23 - 64) 70 (66 - 79) <0.001
Female 12 (44.4%) 8 (72.7%) 0.16
Systolic blood pressure, mmhg 140 (120 - 148) 150 (142 - 161) 0.028
diastolic blood pressure, mmhg 85 (80 - 93) 90 (85 - 90) 0.625
Serum Creatinine, µmol/l 325 (243 - 637) 400 (349 - 665) 0.132
Proteinuria, g/du 1.55 (0.9 - 2.3) 1.23 (0.63 - 2.53) 0.497
egFr (CKd-ePi), ml/min/1.73 m2 15 (8 - 26) 11 (6 - 15) 0.023
Active urine sediment 26 (96.3%) 8 (80%) 0.172
nephrotic syndrome 5 (18.5%) 1 (10%) 0.146
pAnCA 20 (74.1%) 10 (90.9%) 0.395
Age is expressed as median (min-max); all other measurements are expressed as either median (interquartile range) or 
number (%)
Table 2. Clinical parameters at the end of follow-up period
< 65 years old ≥ 65 years old
P
n = 25 n = 7
Systolic blood pressure, mmhg 140 (120 - 150) 130 (126 - 138) 0.428
diastolic blood pressure, mmhg 90 (81 - 90) 80 (76 - 87.5) 0.051
Serum Creatinine, µmol/l 150 (114 - 209.5) 191 (130 - 393) 0.175
Proteinuria, g/du 0.53 (0.26 - 0.55) 0.55 (0.32 - 1.42) 0.765
egFr (CKd-ePi), ml/min/1.73 m2 44 (25.5 - 54) 25 (10 - 37) 0.068
time to infectious complications, months 4 (2 - 8.3) 3 (1 - 6) 0.601
nephrotic syndrome 2 (8,3%) 0 (0%) 0.43
pAnCA 7 (41,9%) 4 (57,1%) 0.659
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dominantly the elderly (10, 90.9%). Arterial hyperten-
sion was the most frequent comorbid disease.
There was no significant difference in induction 
treatment regimen between the groups. The elderly co-
hort was most frequently treated with a combination 
of cyclophosphamide and CS (9, 81.8%), while the 
younger group was predominantly treated with a com-
bination of CS and either cyclophosphamide or ritux-
imab (16, 59.2%). CS monotherapy as a regimen 
choice was used more frequently in the younger popu-
lation (11, 40.7% vs. 2, 18.2%). That was the group of 
patients treated at the beginning of the 1990s. Plasma-
pheresis was done in 6 (16.2%) patients overall, with 
no difference between younger than 65 and the elderly 
(4, 15.4% vs. 2, 18.2%; P = 0.833).
The groups had similar follow-up duration (38.5 
months, iQr 15.5 - 55.75, vs. 32 months, iQr 3 - 
110; P = 0.820). After 2 years of follow-up, 11 (84.6%) 
younger and 4 (66.7%) older patients were still on iS. 
Combination of oral CS and AZA was the most com-
monly found maintenance therapy in the younger 
group (6, 46.2%), while in the older group, the most 
commonly found therapy was oral CS monotherapy 
(in 3, 50%). At the end of follow-up, 48.1% of total 
patients had no iS.
At the end of follow-up there was no difference 
between younger and older group in renal function pa-
rameters like egFr (44 ml/min/m2, iQr 25.5 - 54, 
vs. 25 ml/min/m2, iQr 10 - 37), daily proteinuria 
(0.53 g, iQr 0.26 - 0.55 vs. 0.56 g, iQr 0.32 - 1.42), 
or systolic blood pressure (140 mmhg, iQr 120 - 150, 
vs. 130 mmhg, iQr 126 - 138; P > 0.05) (table 2).
Both groups had significant beneficial effects on 
kidney outcome parameters during the follow-up pe-
riod. According to KdigO guidelines, 24 (64.9%) of 
all patients had favourable renal outcomes, with no 
difference between the groups (17, 65.4%, vs. 7, 63.6%; 
P = 0.919). Patients with favourable renal outcomes 
are comprised of 6 (23.1%) vs. 1 (9.1%) total re-
missions, 11 (42.3%) vs.6 (54.5%) partial remissions 
(table 3). unfavourable renal outcomes comprised of 
eSrd cases, as well as 3 cases of active and still not 
terminal renal disease in the younger group. ten pa-
tients (26.3%) at the end of follow-up had eSrd and 
required renal replacement therapy (rrt) with no 
difference between the younger and older group (in 6, 
22.2 %, vs.4, 36.4 %; P = 0.369). we found no differ-
ence in time to rrt between the groups (9 months, 
iQr 1 - 38, vs.2.5 months, iQr 1.2 - 90.7; P = 0.05). 
more importantly, half of the patients who initially 
presented with eSrd or a need for rrt recovered 
their renal function upon iS, similarly in older as in 
the younger group (5, 45.4% vs.8, 57.1%). eSrd-free 
survival was similar between groups (Figure 1.) in 
multiple logistic regression analysis, higher Bmi at 
presentation was a protective factor for the develop-
ment of eSrd (Or 0.629, 95% Ci 0.411 - 0.962, 
P = 0.032).
infective complications were recorded in 7 (63.6%) 
patients in the older cohort and 10 (47.6%) patients in 
the younger group. The difference in the frequency of 
infectious complications was not significant between 
the two groups (P = 0.388). The most common infec-
tions were urinary tract infections (uti), with 2 
(9.1%) cases in the younger and 3 (30%) in the older 
population. Also, patients in the older group were 
more prone to gram-positive sepsis (in 3 of them, 
30%). There was no significant difference in time in 
developing the infectious complications between 
groups (P = 0.601).
There was no difference in occurence of malignant 
diseases among groups (in 1 younger, 3.7 %, vs.1 older, 
9.1 %; P = 0.5). Seven patients died during follow-up, 
with no significant difference between two groups (3, 
14,8% vs.4, 27,3%; P = 0.369).
Figure 1. End-stage renal disease (ESRD)  
- free survival in older (7, 63.4%) and younger  
(21, 77.8%) groups
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Discussion
The most common cause of rPgn in the elderly is 
AnCA - gn. in fact, this entity is so common in the 
elderly that in patients with positive serology, histo-
logical confirmation might not even be necessary12,13. 
Our results further confirm these findings, with all pa-
tients in our cohort being AnCA positive and 78.9% 
pAnCA positive. however, even if a diagnosis could 
probably be made without histological confirmation, 
the delay in AnCA serology testing results in everyday 
practice would result in an impediment of diagnosis 
and worse outcome. Therefore, kidney biopsy remains a 
vital diagnostic procedure, and all patients in our study 
had histological confirmation of the diagnosis.
There are conflicting results in the literature regard-
ing the treatment of elderly patients with AAv, with a 
number of studies reporting an increased risk of infec-
tion, leucopenia, and even increased mortality14,15. The 
increase in mortality was primarily attributed to death 
from infections occurring during immunosuppression15. 
however, comparable rates of renal outcome, as well as 
the similar risk of infection in comparison with younger 
AnCA-gn patients, were also reported4,6,16.
in our retrospective study, due to the high index of 
active crescent formations on kidney biopsy and rap-
idly progressive pauci-immune glomerulonephritis, all 
patients were treated with iS, which gave us the op-
portunity to compare older to younger group of pa-
tients with AnCA-gn. we found no significant dif-
ference regarding the renal outcome as well as no sig-
nificant difference in the risk of infection between the 
two groups. As the elderly group was treated with 
combination therapy, not having a difference in the 
frequency of infection is an important fact. Further-
more, we observed no significant difference in mortal-
ity between the two groups. likewise, in our study, the 
deaths were not preceded by the development of 
eSrd in both groups, which was contrary to the lit-
erature statement that older patients were more likely 
to die before progressing to eSrd4-6.
interestingly, higher Bmi at presentation was an 
independent protective factor against the development 
of eSrd. it may be that this phenomenon has some-
thing to do with reverse epidemiology in eSrd, where 
higher Bmi is better for patients’ outcome than mal-
nutrition. Although kidney function at presentation 
was reported as an independent factor of renal and 
overall survival4,6,11,17-21, we did observe such a trend, 
but without reaching statistical significance.
importantly, over 50% of patients on rrt at pre-
sentation recovered kidney function after the treat-
ment. Similar results were reported by manno et al., 
who found that 40% of patients with pauci-immune 
glomerulonephritis that required haemodialysis at the 
presentation after iS recovered their renal function re-
gardless of age22. The fact that renal function can im-
prove with treatment in a significant proportion of 
patients, even if the patients presented with the need 
for rrt, gives a strong argument for administering iS 
even in elderly patients. Although it is plausible that 
this population of patients harbours an increased risk 
of infections, the benefit of avoiding rrt therapy and 
its complications should certainly be taken into ac-
count in clinical decision making1. ultimately, the de-
cision to administer treatment of rPgn in the elderly 
should not be based on age alone since it is obvious 
that a subpopulation of elderly patients has a clear 
benefit from iS. Further studies are needed to recog-
nize this specific patient subpopulation, thus avoiding 
treating patients with a low probability of treatment 
success. Furthermore, more studies are needed to in-
vestigate the magnitude of the risk of infection in this 
population of patients more accurately.
The main limitations of this study are the retro-
spective design and sample size, diversity in therapeu-
tic approaches, and histological results over decades. 
As AAv and especially AnCA-gn is a relatively rare 
disease, multicentric prospective research and collabo-
ration would be most welcome and would bring more 
power to results and conclusions drawn from them, 
particularly when dealing with a specific subgroup of 
patients, like the elderly and the very elderly.
in conclusion, when facing the challenge of treat-
ing older patients with kidney damage due to AnCA-
gn, age alone should not guide our decision because 
renal recovery after iS can be expected, even in ini-
tially severe renal failure.
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Sažetak
iShOd StAriJih BOleSniKA S AnCA glOmerulOneFritiSOm  
liJeČenih imunOSuPreSivnOm terAPiJOm
K. Kurtov, M. Laganović, S. Karanović, Ž. Dika, E. Ivandić, M. Živko, J. Kos,  
M. Fištrek, B. Jelaković i I. Vuković Brinar
najčešći uzrok brzoprogresivnog glomerulonefritisa u starijih je glomerulonefritis s antineutrofilnim citoplazmatskim 
protutijelima (AnCA-gn, od eng. antineutrophil cytoplasmic antibody related glomerulonephritis), a s obzirom na komorbi-
ditete predstavlja izazov u odluci oko primjene imunosupresivne terapije (iS). Cilj ovog istraživanja je usporediti razlike u 
ishodu dvije dobne skupine bolesnika.
istraživanje je obuhvatilo slučajeve AnCA-gn ograničenih na bubrege, liječene od 1990. do 2018. godine, njih 38 
(18 muških), od kojih 11 ima 65 ili više godina (medijan 70, min.-max. 66 - 79 godina) a 27 mlađih (medijan 55, min. - max. 
23 - 64 godina). Svi bolesnici su liječeni monoterapijom ili kombinacijom iS-a.
najčešće primjenjena iS u starijoj populaciji bila je kombinacija intravenskog ciklofosfamida i kortikosteroida (KS) (u 9 
(81,8%)), u mlađoj kombinacija KS s ciklofosfamidom ili rituksimabom (59,2%). Stariji pacijenti imali su sličnu učestalost 
smrtnosti (3, 14,8% vs 4, 27,3%; P = 0.369), zloćudnih bolesti (1, 3,7% vs 1, 9,1%; P = 0.5) i infektivnih komplikacija (10, 
46,7% vs 7, 63,6%); P = 0.388). deset bolesnika je na kraju praćenja bila ovisno o nadomještanju bubrežne funkcije (nBF) 
bez razlike u dobnoj skupini (6, 22,2% vs 4, 36,4%; P = 0.369). međutim, od inicijalne potrebe nBF-om se uz iS oporavila 
polovica starijih i mlađih bolesnika.
naši rezultati su u skladu trenutačnim stajalištima koja podupiru primjenu iS terapije kod starijih bolesnika sa 
AnCA-gn zbog usporedivih ishoda i rizika komplikacija kao u mlađih bolesnika.
Ključne riječi: Antineutrofilna citoplazmatska antitijela, glomerulonefritis, stariji, imunosupresija, mortalitet, kronično bubrež-
no zatajenje
